Project Name: Multiple Sclerosis (MS) Capacity Redesign
Project Summary:
The CWP aims to foster collaboration between Novartis Pharmaceuticals UK Limited (Novartis), East Suffolk and North Essex NHS Foundation Trust (ESNEFT) and NHS Suffolk and North East Essex Integrated Care Board (ICB), to enhance the multiple sclerosis service delivery for patients with relapsing remitting multiple sclerosis (RRMS). Through this partnership, the Parties seek to leverage their combined expertise to improve patient outcomes and streamline healthcare processes. The ultimate goal is to develop innovative solutions that address the challenges faced by patients diagnosed with relapsing remitting multiple sclerosis, and provide more efficient, effective care.
Success of the CWP will be measured by the following KPIs:
- The increase in patients receiving a high efficacy treatment (HET) where appropriate i.e., as more patients are being reviewed there is a potential for an increase in the number of patients who are eligible to receive HET.
- The total number of proactive patient reviews to assess suitability for high efficacy treatment (HET).
- The increase in the number of patient reviews in the duration of the CWP, from a baseline that will be established in Milestone 2 of this CWP.
- The number of patients on the caseload of the new model of care (the MS service with the CWP activity), from a baseline that will be established in Milestone 2 of this CWP.
By continuously monitoring these metrics, the CWP seeks to ensure tangible improvements in healthcare provision and patient well-being.
Milestones:
Milestone 1: CWP kick-off meeting.
Milestones 2: Recruitment of the CWP role, clinic protocols, defining roles and responsibilities. Commencement of data analysis for baseline measures. The development of a questionnaire for Patient Reported Experience Measures (PREMs) and a standard operating procedure (SOP) for patients to support the transition of care.
Milestone 3: Project Role commences training and onboarding.
Milestones 4 to 11: Clinic activity with data submission and CWP review every 3 months..
Milestone 7: Development of case studies to demonstrate efficiencies/ impact of the CWP.
Milestone 12: Development of a service evaluation paper for future funding which shall include case studies started at milestone 7.
Milestone 13: CWP wrap up. CWP outcomes.
Expected Benefits:
Patient.
- Improved patient outcomes due to faster time from referral to treatment time.
- Following the implementation of clinical reviews, more patients might be receiving the appropriate treatment.1
- Enhanced patient experience of the NHS MS service by reducing unnecessary waiting times.
- Care closer to home for those patients being repatriated to the CW Partner’s MS service from Cambridge University Hospital.
ESNEFT.
- Improved quality of care.
- Reduction in patient waiting lists.
- Improved MDT efficiency and outcomes.
- Improved the experience of staff by spreading workload.
Novartis.
- Novartis is likely to see positive outcomes as a result of the CWP with East Suffolk and North Essex NHS Foundation Trust (ESNEFT) and NHS Suffolk and North East Essex Integrated Care Board (ICB); By enhancing the multiple sclerosis service delivery, the CWP aims to improve patient outcomes for those patients with relapsing remitting multiple sclerosis (RRMS). As more patients are reviewed, there is potential for greater utilization of Novartis's medicines, in line with national and local guidelines, where appropriate, leading to improved patient care.
- Better understanding of the RRMS patient management pathway, improved understanding of the pressure points and priorities associated with the MS service. This will enable Novartis to build better projects in this therapy area in other regions of the UK.
Start Date & Duration: September 2025 for 36 months or CWP completion, whichever should first occur.
FA-11471927 | September 2025